

FOI REF: 26/630

28th September 2026

Eastbourne District General Hospital

Kings Drive
Eastbourne
East Sussex
BN21 2UD

Tel: 0300 131 4500
Website: www.esht.nhs.uk

Further to your recent request for information made under the Freedom of Information Act (FOIA) 2000, I now set out our answers to your specific questions, and any clarifications sought and provided, as follows:

Q1. How many new patients were treated for any condition by the Trust's Dermatology Department in the latest 3-month period of April, May and June 2026 (or the latest 3 months available) with the treatments I have provided below?

If you are able to, could you please provide the split of new patients who received their treatment for Psoriasis.

Please can you define a "new patient" as a patient who is receiving any of the treatments listed below for the first time. If a patient received any of the below treatments in 2024 or previous years, they can be classed as a new patient for this period.

	Total Dermatology Department	Psoriasis
Adalimumab [Humira]	0	0
Adalimumab [All Biosimilars]	9	8
Apremilast [Otezla]	1	1
Apremilast [Generic]	4	4
Etanercept [Enbrel]	0	0
Etanercept [All Biosimilars]	0	0
Infliximab [Remicade]	0	0
Infliximab [All Biosimilars]	0	0
Ustekinumab [Stelara]	0	5
Ustekinumab [All Biosimilars]	5	0
Bimekizumab [Bimzelx]	0	0
Brodalumab [Kyntheum]	0	0
Certolizumab [Cimzia]	0	0
Deucravacitinib [Sotyktu]	0	0
Dimethyl Fumarate [Skilarence]	0	0
Guselkumab [Tremfya]	0	0

	Total Dermatology Department	Psoriasis
Ixekizumab [Taltz]	0	0
Risankizumab [Skyrizi]	2	2
Secukinumab [Cosentyx]	1	1
Spesolimab [Spevigo]	0	0
Tildrakizumab [illumetri]	0	0

Q2. How many new patients were treated for any condition by the Trust's Rheumatology Department in the latest 3-month period of April, May and June 2026 (or the latest 3 months available) with the treatments I have provided below?

If you are able to, could you please provide the split of new patients who received their treatment for Axial Spondyloarthritis (axSpA), Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA).

	Total Rheumatology Department	Axial Spondyloarthritis (axSpA)	Rheumatoid Arthritis (RA)	Psoriatic Arthritis (PsA)
Abatacept [Orencia]	4		4	0
Adalimumab [Humira]	1	0	0	1
Adalimumab [All Biosimilars]	41	1	21	8
Apremilast [Otezla]	0			0
Apremilast [Generic]	0			0
Baricitinib [Olumiant]	0		0	
Bimekizumab [Bimzelx]	3	0		1
Certolizumab [Cimzia]	1	0	0	0
Etanercept [Enbrel]	0	0	0	0
Etanercept [All Biosimilars]	7	0	4	1
Filgotinib [Jyseleca]	3		3	
Golimumab [Simponi]	0	0	0	0
Golimumab [All Biosimilars]	8	0	4	4
Guselkumab [Tremfya]	0		0	0
Infliximab [Remicade]	1	0	0	0
Infliximab [All Biosimilars]	12	0	1	2
Ixekizumab [Taltz]	1	0		1

	Total Rheumatology Department	Axial Spondyloarthritis (axSpA)	Rheumatoid Arthritis (RA)	Psoriatic Arthritis (PsA)
Risankizumab [Skyrizi]	0			0
Rituximab [MabThera]	2		2	
Rituximab [Biosimilars]	26		17	
Sarilumab [Kevzara]	0		0	
Secukinumab [Cosentyx]	8	0		3
Tocilizumab [RoActemra]	2		2	
Tocilizumab [Biosimilars]	11		9	
Tofacitinib [Xeljanz]	1	0	1	0
Upadacitinib [Rinvoq]	1	0	0	1
Ustekinumab [Stelara]	0			0
Ustekinumab Biosimilar	3			0

I trust this information is helpful in its detail or explanation however, if you are dissatisfied with the response, then you have the right to request an internal review. If you wish to seek an internal review, please write to the Freedom of Information Team at esh-tr.foi@nhs.net quoting the above FOI reference number, within 40 working days. Please note the Trust is not obliged to accept a request for an internal review after this time period.

Yours faithfully

Freedom of Information (FOI) Team
East Sussex Healthcare NHS Trust
0300 131 4716
Core Hours of Business: Monday to Friday 9.00am to 4.00pm